Last 40 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -12.26 | 13.97 | — | — | — | — | — | — | — | — | — | — | — | — | 5.67 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 148.97 | 55.83 | 334.19 | — | — | — | — | — | — | — | — | — | — | 560.30 | 3.53 | 22.38 | 89.84 | 266.18 | 17.25 | 23.41 | 108.85 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | +110.5% | -79.5% | -4.4% | -17.5% | -8.4% | -83.6% | -89.3% | +1183.6% | |
| P/B Ratio | 3.47 | 4.29 | 5.77 | 3.87 | 2.86 | 2.70 | 2.34 | 2.07 | 2.82 | 3.74 | 2.83 | 2.11 | 2.88 | 2.54 | 3.50 | 3.25 | 3.54 | 4.67 | 4.09 | 4.30 | 5.66 |
| — | +58.6% | +147.0% | +86.6% | +1.4% | -27.8% | -17.4% | -1.5% | -2.0% | +47.4% | -19.3% | -35.3% | -18.8% | -45.6% | -14.4% | -24.3% | -37.4% | -23.0% | -54.5% | -31.2% | -39.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5.91 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 14.66 | — | — | — | — | — | — | — | — | — | — | — | — | 5.99 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 98.9% | 97.4% | — | — | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | — | -713.0% | -3622.1% | — | — | — | — | — | — | — | — | — | — | -8981.5% | 58.0% | -343.8% | -1024.4% | -3020.1% | -117.0% | -157.8% | -616.3% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -197.4% | +149.5% | -117.9% | -66.2% | -86.5% | +56.6% | +82.4% | -899.9% | |
| Net Margin | — | 394.5% | -3539.2% | — | — | — | — | — | — | — | — | — | — | -7841.6% | 62.3% | -312.4% | -959.6% | -2902.5% | -112.0% | -154.8% | -601.4% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -170.2% | +155.7% | -101.9% | -59.6% | -81.3% | +57.7% | +82.5% | -878.1% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.7% | 8.0% | -14.5% | -13.2% | -13.3% | -13.0% | -11.5% | -11.3% | -9.0% | -7.9% | -7.0% | -8.2% | -11.1% | -8.6% | 17.0% | -10.9% | -10.6% | -12.2% | -6.5% | -6.9% | -7.6% |
| — | +161.3% | -25.4% | -17.1% | -47.1% | -64.0% | -65.7% | -38.1% | +19.0% | +8.1% | -140.9% | +25.1% | -4.4% | +29.2% | +361.0% | -57.5% | -39.7% | -50.2% | -17.1% | -11.7% | -131.6% | |
| ROA | -40.7% | 5.8% | -10.5% | -10.7% | -11.7% | -11.4% | -10.2% | -10.1% | -8.1% | -7.3% | -6.4% | -7.4% | -10.0% | -7.8% | 13.5% | -7.7% | -7.3% | -8.2% | -4.5% | -4.8% | -5.3% |
| — | +150.9% | -3.3% | -6.0% | -44.0% | -57.5% | -58.6% | -35.0% | +18.8% | +7.2% | -147.5% | +2.7% | -36.1% | +4.7% | +400.2% | -59.8% | -39.2% | -43.4% | -13.3% | -7.7% | -128.8% | |
| ROIC | -42.7% | -11.0% | -15.8% | -14.5% | -11.9% | -11.4% | -9.9% | -9.8% | -8.2% | -7.0% | -6.2% | -7.4% | -10.0% | -8.0% | 12.4% | -9.8% | -9.6% | -10.4% | -5.5% | -6.2% | -8.2% |
| — | +3.4% | -59.7% | -47.0% | -46.2% | -62.6% | -58.7% | -33.9% | +18.6% | +12.5% | -150.3% | +25.3% | -4.2% | +23.3% | +323.9% | -58.8% | -18.0% | -8.6% | +17.1% | +15.8% | -129.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.26 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.08 | 0.07 | 0.07 | 0.07 |
| — | +451.4% | -27.4% | -0.2% | -8.5% | +20.4% | +29.0% | +24.7% | -21.8% | -17.4% | -24.9% | -41.2% | -12.5% | -37.0% | -32.6% | -13.6% | -13.0% | +18.7% | +12.1% | +11.5% | +11.1% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.32 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.16 | 6.21 | 8.37 | 9.28 | 9.16 | 9.79 | 10.27 | 9.56 | 8.46 | 9.98 | 12.46 | 11.79 | 13.65 | 16.06 | 17.65 | 3.39 | 3.77 | 3.16 | 3.20 | 2.90 | 2.37 |
| — | -36.6% | -18.5% | -2.9% | +8.3% | -1.9% | -17.6% | -18.9% | -38.0% | -37.9% | -29.4% | +247.9% | +261.9% | +408.6% | +451.3% | +17.0% | +59.0% | -83.8% | -87.7% | -89.0% | -88.6% | |
| Quick Ratio | 9.16 | 5.94 | 8.32 | 9.28 | 9.16 | 9.79 | 10.27 | 9.56 | 8.46 | 9.98 | 12.46 | 11.79 | 13.65 | 16.06 | 17.65 | 3.39 | 3.77 | 3.16 | 3.20 | 2.90 | 2.37 |
| — | -39.4% | -18.9% | -2.9% | +8.3% | -1.9% | -17.6% | -18.9% | -38.0% | -37.9% | -29.4% | +247.9% | +261.9% | +408.6% | +451.3% | +17.0% | +59.0% | -83.8% | -87.7% | -89.0% | -88.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 40 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DNLI stock.
Denali Therapeutics Inc.'s current P/E is -12.3x. The average P/E over the last 1 quarters is 14.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Denali Therapeutics Inc.'s business trajectory between earnings reports.